CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study This study includes the PanCareSurFup and ProCardio cohort of ≥ 5 ...
Erratum: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer Risk Factors for Primary Bone Cancer After Childhood Cancer: ...
Saliva molecular testing showed strong accuracy for pulmonary tuberculosis. Read more about this nonsputum diagnostic ...
Biomarker changes that occur in the period between normal cognition and the diagnosis of sporadic Alzheimer’s disease have not been extensively investigated in longitudinal studies. We conducted a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results